Compare Cytokinetics Inc (CYTK) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Home Depot Inc — how do they compare? Cytokinetics Inc trades at $82.39 (market cap $11.12B), while Home Depot Inc trades at $343.57 (market cap $336.77B). The key difference: Home Depot Inc is far larger — about 30.3× Cytokinetics Inc's market cap, and Home Depot Inc pays a 2.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | HD | |
|---|---|---|
Market Cap | $11.12B | $336.77B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $423.42 |
52-Week Low | $33.23 | $297.51 |
Enterprise Value | $11.59B | $398.32B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Home Depot (HD) trades at $345.00, up 2.34% with recent earnings showing mixed results including a Q3 2025 miss but Q4 2025 and Q1 2026 beats. The stock faces technical bearish signals despite strong fundamentals with $159.51B revenue and 8.41% net margin. Analyst consensus remains bullish with a $370.59 price target, though institutional activity shows mixed positioning amid housing market headwinds.
The outlook balances strong Pro segment growth and dividend reliability against weakening big-ticket demand and margin pressure. With the stock near key support at $336, upside exists if housing recovers, but rising rates and competitive pressures pose near-term risks to earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
